Rotate device

Please turn your device

Bormioli Pharma and Stevanato Group sign a collaboration agreement for glass molded vials in EZ-fill® configuration

Bormioli Pharma 05 February 2020

February 5, 2020 – Stevanato Group, through Ompi, its specialist in glass primary packaging for the pharmaceutical industry, and Bormioli Pharma announce today a collaboration agreement.
The agreement will enable biopharma customers, contract filling organizations, and research laboratories to receive Bormioli Pharma’s proprietary primary containers in Ompi’s industry-recognized EZ-fill® secondary packaging configuration.
Bormioli Pharma glass vials supplied in Ompi’s packaging configurations can be processed into existing fill-finish lines. EZ-fill® secondary packaging is designed to mitigate the risk of breakages, cosmetic issues, and particulate generation. It is the ideal solution from lab-scale manual filling up to the traditional filling process, allowing to accelerate the commercialization of pharmaceutical and biologics.

Andrea Zambon, Marketing & Product Management Director at Stevanato Group, said: “It is with great pride that we announce the agreement with Bormioli Pharma. EZ-fill® technology has over the years become the market standard and the reference in secondary packaging. Lean processes, flexibility, and ease of use are EZ-fill® key pillars, responding to the market’s rising demand for cost-efficient, scalable solutions. Customers can now count on an additional established player for the supply of ready-to-use parenteral vials.”

Andrea Sentimenti, Marketing & Innovation Director at Bormioli Pharma said: “As a partner of the pharma industry, we strive every day to go beyond the product, building dedicated services around it. The agreement with Stevanato Group is one more step forward in this direction and allows us to combine the high quality of our parenteral vials with the reliability of EZ-fill® technology. The result is a premium packaging solution for parenteral drugs, engineered to overcome the challenges of the most demanding injectables.”

Bormioli Pharma 05 February 2020